Kos Niaspan/Simvastatin Combination NDA Planned For 2006
This article was originally published in Pharmaceutical Approvals Monthly
Kos is targeting an NDA for its Niaspan/simvastatin combination product for 2006, following the completion of two pivotal trials in patients with mixed dyslipidemia.
You may also be interested in...
Obesity market could see two near-term entrants, Pfizer says. Sanofi-Aventis will submit Acomplia in early Q2 2005; Regeneron’s Axokine is in Phase III. Pfizer is looking at combination therapy for metabolic syndrome, including Caduet and atorvastatin/torcetrapib. Firms are focusing on cardiovascular benefits
Novo Nordisk and Aradigm may focus on type 2 diabetes only for their AERx iDMS inhaled insulin system NN1998 following disappointing glucose suppression results in a Phase III type 1 diabetes trial.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011